Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Collaboration to identify patient-selection biomarkers for Cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment Collaboration to identify patient-selection biomarkers for Cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021. A pre-recorded corporate presentation will be available on-demand beginning on Thursday, Nov. 18 and will remain available for 30 days in the investor section of the Cyclerion website. Management will be available for one-on-one meetings and investors may request a meeting through Jefferies.

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS)

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Color Star Technology

GSX Techedu Inc.

Inpixon

Kosmos Energy

Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?

Trending Penny Stocks to Buy Now? 5 to Watch This Week

Truist analyst Joon Lee has initiated coverage of Cyclerion Therapeutics Inc (NASDAQ:CYCN) with a Buy rating and price target of $14, suggesting a massive 374% upside. The development of drugs targeting the brain's nitric oxide (NO) system is "ripe for therapeutic intervention," the analyst tells investors.

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerion's CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment.

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies.  This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Boxlight

China Xiangtai Food Co Ltd

Vislink Technologies Inc

Which penny stocks on Reddit are you watching? Here's 4 for some watchlist inspiration The post Best Penny Stocks on Reddit to Buy?

Best Penny Stocks on Reddit to Buy? Check These 4 Out in June

Agenus

MoSys

Meme penny stocks are heating up; are these 3 on your watchlist? The post Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist

Akebia Therapeutics

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the development and commercialization of praliciguat. Under the terms of the agreement, Akebia will be solely responsible for the research, development, and commercialization of praliciguat globally.

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

Cyclerion eligible to receive up to $585 million in potential future development and commercial milestone payments, and tiered sales-based royalties

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY3018 program Proceeds to fund ongoing clinical development of CY6463 and advancement of next generation CY3018 program

Cyclerion Therapeutics Announces $18 Million Private Placement

Series of preclinical studies demonstrate the therapeutic potential of CY6463, a first-in-class, CNS-penetrant sGC stimulator

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available for one-on-one meetings and investors may request a meeting through Jefferies.

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Jaguar Health

Kaixin Auto Holdings

After this week's market pullback, some of these penny stocks are trending into the weekend. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 3 To Know Before Next Week

The stock price of Cyclerion Therapeutics Inc (NASDAQ: CYCN) increased by over 5% pre-market. This is why it happened.

News for Cyclerion Therapeutics Inc Stock (CYCN)